MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with a tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Stephen, Martin, Miguel, Di Leo, Angelo, Im, Seock-Ah, Awada, Ahmad, Forrester, Tammy, Frenzel, Martin, Hardebeck, Molly C., Cox, Joanne, Barriga, Susana, Toi, Masakazu, Iwata, Hiroji, Goetz, Matthew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336880/
https://www.ncbi.nlm.nih.gov/pubmed/30675515
http://dx.doi.org/10.1038/s41523-018-0097-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336880/
https://www.ncbi.nlm.nih.gov/pubmed/30675515
http://dx.doi.org/10.1038/s41523-018-0097-z

Ejemplares similares